Read about the top three stories STAT reporters will be tracking in Biopharma throughout 2018
Biotech and pharma face a changing landscape in 2018, as Scott Gottlieb’s FDA makes its mark and political uncertainty rules. But some perennial issues aren’t going away: Widespread anger at the rising cost of drugs shows no sign of abating and the dearth of women in biotech continues.
For a fresh take, read what three women in venture capital have to say about the year to come. Check on patent maneuvers, repatriating cash, and outcomes-based contracts for a view of business developments beyond drug pricing.
We’re keeping an eye on legislative battles (will pharma face user fees for over-the-counter drugs?) as well as advertising strategies (will precision marketing win the day?). We take a look at the gold rush in brain technologies while genetic medicine, therapies based on the microbiome, and artificial intelligence are also gaining ground.
Offered Free by: STAT
See All Resources from: STAT